BACKGROUND AND AIM: Despite the increasing rates of antibiotic resistance, furazolidone-based regimens have demonstrated promise in METHODS: Patients who received BQFT or BQFA as rescue treatment were enrolled in this study. RESULTS: A total of 342 participants were included. BQFT showed significantly higher eradication rates (modified intention-to-treat: 96.2% vs. 76%
per-protocol: 97.1% vs. 77.8%, CONCLUSION: BQFT exhibits superior efficacy with acceptable tolerability, making it a promising option for patients with refractory